BioDerm

BioDerm acquires majority stakes in mature, cash-flowing medical-device product lines within urology, continence care, wound care, and diabetes supplies. The firm targets products with established Medicare and private-payer reimbursement codes where clinician habit creates durable purchasing patterns. It does not invest in early-stage devices, pharmaceuticals, or capital equipment. Acquisitions are funded from operating profits rather than outside limited partners.

BioDerm identifies targets through its clinical training network and direct relationships with hospital supply-chain administrators. The firm's nurse-education programs generate visibility into which product lines are gaining clinician adoption before those products appear in formal sell-side processes. This embedded clinical presence functions as a proprietary sourcing channel distinct from intermediated auctions.

BioDerm is a hybrid — an operating company that reinvests its own cash flows into acquisitions, functioning as a permanent-hold vehicle rather than a committed-capital fund. The firm does not manage third-party capital, making it closer in structure to an internally funded family-office platform than a traditional private equity manager, though its wealth origin is operating profits rather than a family liquidity event.

There is no public record of BioDerm accepting limited-partner commitments or co-investing alongside private equity funds. The firm's acquisition activity is funded entirely from the cash flows of its core manufacturing business, which gives it the ability to hold assets indefinitely without a mandated exit timeline.

BioDerm's manufacturing, distribution, and acquisition activity is concentrated in the United States, with a particular emphasis on the Southeastern region. Its products are distributed nationally through durable medical equipment suppliers, home-health agencies, and Veterans Health Administration procurement contracts. The firm has not disclosed international operations or offshore manufacturing.